Form 4: Core Laboratories Inc. Chairman and CEO, Lawrence Bruno, Reports Acquisition of Performance Shares

Lawrence Bruno, Chairman and CEO of Core Laboratories Inc., reports the acquisition of 202,764 performance shares tied to the company's Return on Invested Capital (ROIC) relative to its Bloomberg Peer Group.

Summary

• Lawrence Bruno, Chairman and CEO of Core Laboratories Inc., filed a Form 4 on February 13, 2025, reporting a transaction involving performance shares.
• He acquired 202,764 performance shares, which will vest based on Core Laboratories' ROIC performance compared to its Bloomberg Peer Group (BPG) over a three-year period from January 1, 2025, to December 31, 2027.
• The vesting schedule is tiered: 50% vests if the company is in the top 35th percentile of ROIC among the BPG, 100% vests if in the top 55th percentile, and 175% vests if at or above the 85th percentile.
• Vesting will occur on January 1, 2028, following the performance period.
• The number of shares vesting between the 35th and 55th percentiles, and between the 55th and 85th percentiles, will be interpolated on a straight-line basis.
• If the absolute total shareholder return is negative for the performance period, the portion of the award exceeding 100% (up to 175%) will be reduced by one-half.
• The award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, aligning management incentives with shareholder value. The performance-based vesting is a positive signal, but the ultimate outcome depends on the company's future performance.

Positives

• The performance-based vesting of shares aligns management's interests with those of shareholders, incentivizing improved ROIC.
• The tiered vesting structure provides multiple levels of achievement and reward.
• The survival of the award under certain termination conditions provides security to the executive.

Risks

• The ultimate value of the performance shares is contingent on Core Laboratories' ROIC performance relative to its peer group, which is subject to market conditions and company execution.
• Negative total shareholder return can reduce the potential payout of the award.

Future Outlook

The vesting of the performance shares is contingent on the company's ROIC performance over the next three years, indicating a focus on improving capital efficiency and shareholder returns.

Industry Context

Performance-based compensation is a common practice in the oilfield services industry to align executive incentives with shareholder value creation. ROIC is a widely used metric to assess capital allocation efficiency.

Comparison to Industry Standards

• Companies like Schlumberger (SLB) and Halliburton (HAL) also utilize performance-based equity compensation, often tied to metrics such as total shareholder return (TSR), revenue growth, and profitability.
• The specific ROIC targets and peer group comparisons will determine how Core Laboratories' compensation structure compares to industry benchmarks.
• The vesting schedule and potential reduction for negative TSR are also common features in executive compensation plans within the sector.

Stakeholder Impact

• Shareholders: The performance-based compensation aims to improve shareholder value through increased ROIC.
• Employees: The compensation structure may influence employee motivation and performance, as it aligns with the company's overall financial goals.
• Management: The vesting of performance shares provides a direct financial incentive for management to achieve specific performance targets.

Next Steps

• Monitor Core Laboratories' ROIC performance over the three-year performance period.
• Track the company's total shareholder return to assess the potential impact on the vesting of the performance shares.
• Review future filings to understand any changes in the compensation structure or performance targets.

Key Dates

Keywords

performance shares, ROIC, Core Laboratories, Lawrence Bruno, Form 4, vesting, Bloomberg Peer Group, compensation